Evidence map›Paper›PMID 33254561›Full record

ArticleMedical hypotheses2020

Potential of electric stimulation for the management of COVID-19.

Prince Allawadhi, Amit Khurana, Sachin Allwadhi, Uma Shanker Navik, Kamaldeep Joshi, Anil Kumar Banothu, Kala Kumar Bharani

Open access · greenAbstract read
In one paragraph

Article in Medical hypotheses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 30 citations in OpenAlex.

  1. Smart stimuli-responsive drug delivery systems in spotlight of COVID-19.Asian journal of pharmaceutical sciences · 2023
    Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Electrical Stimulation for Immune Modulation in Cancer Treatments.Frontiers in bioengineering and biotechnology · 2021
    Review
  14. Review
  15. Sensors international · 2021
    Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Prince AllawadhiDepartment of Pharmacy, Vaish Institute of Pharmaceutical Education and Research (VIPER), PBDS-UHS, Rohtak-124001, Haryana, India.
Amit KhuranaDepartment of Veterinary Pharmacology and Toxicology, College of Veterinary Science (CVSc), PVNRTVU, Rajendranagar, Hyderabad-500030, Telangana, India; Centre for Biomedical Engineering (CBME), Indian Institute of Technology (IIT), Delhi-110016, India. Electronic address: ak3.khurana@gmail.com.
Sachin AllwadhiDepartment of Computer Science and Engineering, University Institute of Engineering and Technology (UIET), Maharshi Dayanand University, Rohtak-124001, Haryana, India.
Uma Shanker NavikDepartment of Pharmacology, School of Basic and Applied Sciences, Central University of Punjab, Bathinda-151001, Punjab, India.
Kamaldeep JoshiDepartment of Computer Science and Engineering, University Institute of Engineering and Technology (UIET), Maharshi Dayanand University, Rohtak-124001, Haryana, India.
Anil Kumar BanothuDepartment of Veterinary Pharmacology and Toxicology, College of Veterinary Science (CVSc), PVNRTVU, Rajendranagar, Hyderabad-500030, Telangana, India.
Kala Kumar BharaniDepartment of Veterinary Pharmacology and Toxicology, College of Veterinary Science (CVSc), PVNRTVU, Rajendranagar, Hyderabad-500030, Telangana, India. Electronic address: bkalakumar@gmail.com.
P.V. Narsimha Rao Telangana Veterinary University · INMaharshi Dayanand University · INCentral University of Punjab · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic is the most devastating health emergency that humans have seen over the past century. The war against the disease has been handicapped by unavailability of effective therapeutic options. Till date, there is no clinically approved vaccine or drug for the treatment of COVID-19, and the ongoing search to find a novel therapy is progressing at pandemic pace. Herein, we propose a novel hypothesis based on sound research evidence that electric stimulation can be a potential adjuvant to the currently used symptomatic therapies and antiviral drugs. Based on preclinical evidence, we propose that electric stimulation can improve respiratory functions, inhibit SARS-CoV-2 growth, reduce pain, boost immunity and improve the penetration of antiviral drugs. We envisage that our hypothesis, if used clinically as an adjuvant, may significantly improve the therapeutic outcomes of the current treatment regimen being used around the globe for the management of COVID-19.

Indexed as

Electric Stimulation TherapyAntiviral AgentsB-LymphocytesCOVID-19HIV InfectionsHumansImmune SystemModels, TheoreticalPain ManagementRespirationRespiration DisordersT-LymphocytesTreatment OutcomeAntiviral AgentsCOVID-19Electric stimulationHypothesisImmunityRespiratory function

Identifiers

PMID33254561
PMCPMC7481069
OpenAlexW3084204749

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.